Idylla cartridge for BRAF testing; © Biocartis

Biocartis launches partnership in liquid biopsy

Belgian liquid biopsy specialist Biocartis Group NV has announced it will co-develop a breast cancer assay with MRC Technology.

Read more
© Becton Dickinson

The Difference of One Simple Sort

One researcher, one sorter, one cell, many discoveries. BD is dedicated to developing easy-to-use cell sorting technologies that simplify accurate and reliable flow cytometry.

Read more
@ Polpharma Biologics

Biomanufacturing: Why single-use?

Established in 2013, Polpharma Biologics is the biotechnology unit of the rapidly growing ­Polpharma Group one of the largest pharmaceutical players in the CEE region. Currently, with over 140 people, four sites, and full expertise for biopharmaceutical development and production, Polpharma Bio­logics is running five projects dedicated to monoclonal antibodies, and is just stepping into the contract development and manufacturing business.
Read more
Renee Aguiar-Lucander

Pharmalink: Launching into Phase III

Pharmalink AB has hired Renee Aguiar-Lucander as Chief Executive Officer. She will lead the expansion and strategic development of the Swedish specialty pharmaceutical company following the clinical success of its orphan drug Nefecon.
Read more
Fcabs are Fc-region with antigen binding sites (in case of FS118: LAG-3) that are inserted into a full size IgG antibody that binds a secondary target via its Fab part (in case of FS118: PD-L1) resulting in a bispecific molecule.: PD-L1), © F-Star Biotechnology

Merck KGaA and F-star in €1bn deal

German Merck KGaA has secured an option on UK’s F-Star Biotechnology Ltd’s preclinical bispecific PD-L1/LAG checkpoint inhibitor FS118 and four candidates in discovery stage.

Read more
James Beaumont

Metrion Biosciences: Developing the business

Cambridge-based specialist ion channel CRO and drug discovery company Metrion Biosciences Ltd has named James Beaumont Head of Business Development. He joins from NZP-Dextra, where he held the post of Development Director.
Read more
Cancer tissue, © Bicycle Therapeutics Ltd.

Bicycle raises £40m

Cambridge-based cancer company Bicycle Therapeutics has raised £40m to advance its clinical pipeline of peptide-based conjugates with antibody-like binding properties. 

Read more
Brexit.pngwikicommons

EC and EMA provide Brexit guidance

UK-based drug developers and contract manufacturers are set to find partners in the European Economic Area (EEA) to uphold Orphan Drug Designation, MAA or transfer their current UK based site of batch release to a location established in the Union.

Read more
Mode of action of allosteric modulation, © Addex Therapeutics Ltd.

Addex further improves liquidity

Following a private placement worth CHF3m in February, Swiss allosteric modulator specialist Addex Therapeutics has increased its capital to finance clinical studies of dipraglurant in Parkinson’s and ADX71441.

Read more
Mark Vossenaar

Gyros Protein Technologies: European Marketing

Gyros Protein Technologies has appointed Mark Vossenaar as Vice President, European Sales.

Read more